Prospective observational cohort study of bevacizumab combined with paclitaxel as the first-or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)

被引：0
|
作者：
Kondo, N. [1 ,11 ]
Yamamoto, Y. [2 ]
Yamashiro, H. [3 ]
Kashiwaba, M. [4 ]
Nakamura, R. [5 ]
Takahashi, M. [6 ]
Toh, U. [7 ]
Tsugawa, K. [8 ]
Narui, K. [9 ]
Tamaki, K. [10 ]
Yoshinami, T.
Ohtani, S. [12 ]
Kai, Y. [13 ]
Takano, T. [14 ]
Yanagita, Y. [15 ]
Morita, S. [16 ]
Toi, M. [17 ]
Ohno, S. [18 ]
机构：
[1] Nagoya City Univ Hosp, Dept Breast Surg, Nagoya, Aichi, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto, Japan
[3] Tenri Hosp, Dept Breast Surg, Nara, Japan
[4] Iwate Med Univ, Dept Surg, Morioka, Iwate, Japan
[5] Chiba Canc Ctr, Dept Breast Surg, 666-2 Nitonacho, Chiba 2608717, Japan
[6] NHO Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan
[7] Kurume Univ Hosp, Dept Surg, Kurume, Fukuoka, Japan
[8] St Marianna Univ, Sch Med Hosp, Div Breast & Endocrine Surg, Dept Surg, Kawasaki, Kanagawa, Japan
[9] Yokohama City Univ, Med Ctr, Dept Breast & Thyroid Surg, Yokohama, Kanagawa 232, Japan
[10] Nahanishi Clin Okinawa, Dept Breast Surg, Naha, Japan
[11] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Clin Oncol, Osaka, Japan
[12] Hiroshima City Hiroshima Citizens Hosp, Dept Breast Surg, Hiroshima, Japan
[13] Ueo Breast Canc Hosp, Dept Surg, Oita, Japan
[14] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan
[15] Gunma Prefectural Canc Ctr, Dept Breast Oncol, Ota, Japan
[16] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[17] Kyoto Univ, Grad Sch Med, Breast Surg, Kyoto, Japan
[18] Canc Inst Hosp JFCR, Ctr Breast Oncol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [31] BEVACIZUMAB PLUS CHEMOTHERAPY IN 2ND LINE METASTATIC COLORECTAL CANCER (MCRC): INITIAL RESULTS FROM ARIES, A SECOND BEVACIZUMAB OBSERVATIONAL COHORT STUDY (OCS)
    Bekaii-Saab, T.
    Bendell, J.
    Cohn, A.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 20 - 20
  • [32] Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer
    Yamashiro, H.
    Yamamoto, Y.
    Schneeweiss, A.
    Mueller, V.
    Gluz, O.
    Klare, P.
    Aktas, B.
    Magdolna, D.
    Buedi, L.
    Piko, B.
    Mangel, L.
    Toi, M.
    Morita, S.
    Ohno, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S367 - S367
  • [33] Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
    Zhang, Yan
    Xu, Junying
    Wang, Qiong
    Ling, Guohong
    Mao, Yong
    Cai, Maohuai
    Yang, Yang
    Mei, Jingfeng
    Han, Zhengxiang
    Feng, Jifeng
    Wu, Yuan
    Shi, Lin
    Wen, Shaodi
    Shen, Bo
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [34] The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
    Tanioka, Hiroaki
    Nagasaka, Takeshi
    Uno, Futoshi
    Inoue, Masafumi
    Okita, Hiroyuki
    Katata, Yosuke
    Kanzaki, Hiromitsu
    Kuramochi, Hidekazu
    Satake, Hironaga
    Shindo, Yoshiaki
    Doi, Akira
    Nasu, Jyunichiro
    Yamashita, Haruhiro
    Yamaguchi, Yoshiyuki
    BMC CANCER, 2019, 19 (01)
  • [35] The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
    Hiroaki Tanioka
    Takeshi Nagasaka
    Futoshi Uno
    Masafumi Inoue
    Hiroyuki Okita
    Yosuke Katata
    Hiromitsu Kanzaki
    Hidekazu Kuramochi
    Hironaga Satake
    Yoshiaki Shindo
    Akira Doi
    Jyunichiro Nasu
    Haruhiro Yamashita
    Yoshiyuki Yamaguchi
    BMC Cancer, 19
  • [36] Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study
    Lamiaa Boulaamane
    Saber Boutayeb
    Hassan Errihani
    BMC Research Notes, 5 (1)
  • [37] WEEKLY PACLITAXEL, CARBOPLATIN AND TRASTUZUMAB (WPCH) AS SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH HER2+METASTATIC BREAST CANCER: RESULTS OF A PHASE II STUDY
    Rozzi, Antonio
    Nardoni, Chiara
    Corona, Michela
    Restuccia, Maria Rosa
    Lanzetta, Gaetano
    ANNALS OF ONCOLOGY, 2009, 20
  • [38] Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).
    Klare, P.
    Foerster, F. G.
    Geberth, M.
    Schneeweiss, A.
    Tesch, H.
    Kuemmel, S.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Schmidt, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] CLINICAL OUTCOMES WITH FIRST-LINE BEVACIZUMAB AND CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER AND A HISTORY OF DIABETES: RESULTS FROM THE ARIES OBSERVATIONAL COHORT STUDY
    Bendell, J.
    Cohn, A.
    Mun, Y.
    Fish, S.
    Sommer, N.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [40] Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
    Kenjiro Aogi
    Kenichi Watanabe
    Masahiro Kitada
    Takafumi Sangai
    Shoichiro Ohtani
    Tomoyuki Aruga
    Hidetoshi Kawaguchi
    Tomomi Fujisawa
    Shigeto Maeda
    Takashi Morimoto
    Nobuaki Sato
    Shintaro Takao
    Satoshi Morita
    Norikazu Masuda
    Masakazu Toi
    Shinji Ohno
    International Journal of Clinical Oncology, 2021, 26 : 1229 - 1236
12345